SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma Interventions:   Drug: SCT-I10A;   Drug: SCT510;   Drug: Sorafenib 200mg Sponsor:   Sinocelltech Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials